CINECA IRIS Institutional Research Information System

RADIN, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.713
EU - Europa 4.251
AS - Asia 3.260
SA - Sud America 668
AF - Africa 106
OC - Oceania 81
Continente sconosciuto - Info sul continente non disponibili 12
Totale 15.091
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.269
CN - Cina 1.456
IT - Italia 1.365
ES - Italia 579
JP - Giappone 416
SG - Singapore 329
IE - Irlanda 320
DE - Germania 309
FR - Francia 285
MX - Messico 251
GB - Regno Unito 245
BR - Brasile 203
SE - Svezia 166
IN - India 164
KR - Corea 161
AR - Argentina 156
CO - Colombia 154
CA - Canada 153
VN - Vietnam 135
NL - Olanda 113
ID - Indonesia 107
PL - Polonia 96
RU - Federazione Russa 90
UA - Ucraina 90
PT - Portogallo 89
TW - Taiwan 86
TR - Turchia 81
AU - Australia 77
FI - Finlandia 70
HK - Hong Kong 64
GR - Grecia 62
RO - Romania 59
CL - Cile 51
AT - Austria 49
IR - Iran 49
BE - Belgio 48
PE - Perù 45
SA - Arabia Saudita 45
DK - Danimarca 44
CH - Svizzera 41
IL - Israele 39
EC - Ecuador 34
EG - Egitto 32
PH - Filippine 21
TH - Thailandia 21
DZ - Algeria 20
RS - Serbia 19
TN - Tunisia 19
MA - Marocco 17
HU - Ungheria 16
BG - Bulgaria 15
CZ - Repubblica Ceca 15
PK - Pakistan 15
SI - Slovenia 13
CR - Costa Rica 12
MY - Malesia 11
NO - Norvegia 11
VE - Venezuela 11
EU - Europa 10
GT - Guatemala 9
IQ - Iraq 9
UZ - Uzbekistan 9
BO - Bolivia 7
QA - Qatar 7
EE - Estonia 6
MT - Malta 6
UY - Uruguay 6
HR - Croazia 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
DO - Repubblica Dominicana 4
LB - Libano 4
LT - Lituania 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
SV - El Salvador 4
BY - Bielorussia 3
JO - Giordania 3
KW - Kuwait 3
LI - Liechtenstein 3
AM - Armenia 2
CU - Cuba 2
CY - Cipro 2
GH - Ghana 2
JE - Jersey 2
LK - Sri Lanka 2
MO - Macao, regione amministrativa speciale della Cina 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
SC - Seychelles 2
TJ - Tagikistan 2
A1 - Anonimo 1
AL - Albania 1
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
Totale 15.076
Salva come PNG Salva come JPEG
Città #
Redwood City 517
Chandler 503
Ann Arbor 432
Fairfield 416
Beijing 346
Dublin 309
Ashburn 271
Singapore 259
Torino 245
Santa Clara 244
Woodbridge 219
Wilmington 205
Houston 193
Seattle 168
Turin 162
Shanghai 136
Sesto San Giovanni 130
Cambridge 129
Columbus 107
Madrid 95
Tokyo 95
Medford 91
Nyköping 91
Jakarta 87
Dearborn 86
Lubbock 83
New York 82
Princeton 80
Guangzhou 78
Pisa 76
Dong Ket 72
Milan 67
Hangzhou 66
Nanjing 63
Rome 61
Buenos Aires 59
Jacksonville 56
Barcelona 52
San Diego 48
Bogotá 46
Taipei 46
Mexico City 45
Warsaw 44
Boston 43
Helsinki 43
Villeurbanne 42
Zhengzhou 42
Santiago 41
São Paulo 40
Chengdu 39
Paris 39
Lima 37
Medellín 35
Berlin 33
Hebei 33
Jinan 31
Chicago 30
Los Angeles 29
Athens 28
Seoul 28
Hanoi 26
Changsha 25
Fuzhou 25
Hyderabad 25
Loma Linda 25
London 25
Mexico 25
Toronto 25
Duncan 24
Mumbai 24
Munro 24
Wuhan 24
Chongqing 23
Giussano 23
Hong Kong 23
Vienna 23
Ankara 22
Lisbon 22
Brussels 21
Ottawa 21
Riyadh 21
Santander 21
Quito 20
Shenyang 19
Tianjin 19
Córdoba 18
Kansas City 18
Birmingham 17
Delhi 17
Bologna 16
Central District 16
Cuauhtémoc 16
Guadalajara 16
Kunming 16
Sydney 16
Belgrade 15
Cairo 15
Falls Church 15
Hefei 15
Norwalk 15
Totale 8.089
Salva come PNG Salva come JPEG
Nome #
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review 1.333
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents 1.022
Current insights in obstetric antiphospholipid syndrome 637
The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction 517
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence 515
Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review 497
Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review 482
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome 469
Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials 461
Pregnancy outcomes in mixed connective tissue disease: a multicentre study 427
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: A pooled analysis 403
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study 399
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab 349
The risk of ischaemic stroke in primary APS patients: a prospective study 305
Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? 303
Treatment of antiphospholipid syndrome 275
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome 269
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome 237
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management 233
Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring 230
Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS 201
Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score 174
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study 173
The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study 166
Antiphospholipid antibodies: crossroads between autoimmunity and infections? 164
Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay 160
Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin autoantibodies in antiphospholipid syndrome: A multicenter study 152
Infodemiology of systemic lupus erythematous using Google Trends 148
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis 145
Thrombotic antiphospholipid syndrome 138
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris 135
Filling the gap in antiphospholipid syndrome diagnosis: a patient's story 129
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome 126
Antiphospholipid antibodies negativization: Time for testing for non-criteria aPL? 121
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort 119
Prevalence and Thrombotic Risk Assessment of Anti-beta(2) Glycoprotein I Domain I Antibodies: A Systematic Review 118
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss 118
Recent advances in the management of systemic lupus erythematosus 112
Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 112
Tailoring tofacitinib oral therapy in rheumatoid arthritis: The TuTORApp—a usability study 101
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 96
Hydroxychloroquine reduces IL-6 and pro-thrombotic status 96
IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients 89
Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis 89
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology 89
Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion 88
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS) 88
Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review 86
Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort 84
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients 83
Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study 83
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease 83
Antiphospholipid Syndrome Is Still a Rare Disease—Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al 82
Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"? 76
Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus 75
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 74
The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience 71
Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation 69
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome 68
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets 66
The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities 65
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies 65
Genetic factors in antiphospholipid syndrome: Preliminary experience with whole exome sequencing 64
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach 61
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome 60
Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients 59
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study 58
Antiphospholipid Antibodies and Infection: Non Nova Sed Nove 55
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol 52
Pregnancy outcomes in Behçet's disease: Results from a monocentric cohort 50
Endothelial dysfunction and cardiovascular risk in lupus nephritis: new roles for old players? 50
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach 50
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies 48
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 47
Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/ prothrombin antibodies 43
Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients 42
Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review 41
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome 40
Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients 39
Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease 37
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 36
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 34
Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies 33
Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head 33
Health inequalities and social determinants of health: The role of syndemics in rheumatic diseases 31
The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes 30
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience 29
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians 29
What can Google and Wikipedia can tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus 28
Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. 27
Renal Fibrosis in Lupus Nephritis 27
Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet’s Disease: A Systematic Review 26
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App 25
Serum Biomarkers of Renal Fibrosis: A Systematic Review 25
New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing 24
2023 ACR/EULAR classification criteria in existing research cohorts: an international study 24
Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study) 21
Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 20
Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study 18
16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends 16
Totale 15.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.252
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.833 0 0 0 0 180 207 249 250 315 241 207 184
2020/20212.793 172 216 291 295 275 206 205 185 226 236 211 275
2021/20222.500 198 208 177 216 271 209 225 178 168 119 238 293
2022/20232.459 211 195 152 177 194 484 176 202 224 110 188 146
2023/20242.340 240 236 170 174 228 212 149 197 70 176 167 321
2024/20251.344 131 241 205 328 439 0 0 0 0 0 0 0
Totale 15.569